Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Trastuzumab Deruxtecan for HER2+ Breast Cancer

February 17th 2018

HER2-Targeted Therapy for HER2 Low-Expressing Breast Cancer

February 17th 2018

Adjuvant Therapy for HER2+ Breast Cancer

February 17th 2018

Refining Neoadjuvant Chemotherapy for HER2+ Breast Cancer

February 17th 2018

Ovarian Suppression in Metastatic HR+ Breast Cancer

February 17th 2018

Neoadjuvant Therapy for HR+ Breast Cancer

February 17th 2018

The Role of Fulvestrant in HR+ Breast Cancer

February 17th 2018

Abemaciclib for HR-Positive Metastatic Breast Cancer

February 17th 2018

Quality of Life for Women with HR-Positive Breast Cancer

February 17th 2018

MONALEESA-7 Trial in Premenopausal HR+ Breast Cancer

February 17th 2018

Other Promising Targets in TNBC

February 15th 2018

Role of the Androgen Receptor in TNBC

February 15th 2018

Combination Therapy for TNBC: Checkpoint Inhibitor + Chemotherapy

February 15th 2018

Checkpoint Inhibitor Monotherapy for TNBC

February 15th 2018

Antibody-Drug Conjugates in Treating TNBC

February 15th 2018

Paclitaxel vs Nab-Paclitaxel in Metastatic TNBC

February 15th 2018

No pCR in Patients After Neoadjuvant Chemotherapy in TNBC

February 15th 2018

Anthracycline-Based Regimens: Perioperative Setting for TNBC

February 15th 2018

Neoadjuvant Therapy in TNBC

February 15th 2018

Combining PARP Inhibitors + Checkpoint Inhibitors in TNBC

February 15th 2018